Effective at the market close on Friday November 13, 2020, MYOK will be removed from the LifeSci Biotechnology Clinical Trials Index and its value will be redistributed to the remaining index components based on their weights.
On October 5, 2020, MyoKardia, Inc. agreed to be acquired by Bristol Myers Squibb for $225.00 per share in cash.
